Switch theme
Sign up to access all valuation multiples
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
1993
338
LTM Revenue $433M
LTM EBITDA $99.6M
$5.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TG Therapeutics has a last 12-month revenue (LTM) of $433M and a last 12-month EBITDA of $99.6M.
In the most recent fiscal year, TG Therapeutics achieved revenue of $329M and an EBITDA of $49.9M.
TG Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TG Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $433M | XXX | $329M | XXX | XXX | XXX |
| Gross Profit | $381M | XXX | $291M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $99.6M | XXX | $49.9M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $93.1M | XXX | $41.9M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $73.5M | XXX | $23.4M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $64.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, TG Therapeutics's stock price is $35.
TG Therapeutics has current market cap of $5.6B, and EV of $5.4B.
See TG Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.4B | $5.6B | XXX | XXX | XXX | XXX | $0.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, TG Therapeutics has market cap of $5.6B and EV of $5.4B.
TG Therapeutics's trades at 16.5x EV/Revenue multiple, and 109.1x EV/EBITDA.
Equity research analysts estimate TG Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TG Therapeutics has a P/E ratio of 75.7x.
See valuation multiples for TG Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5.6B | XXX | $5.6B | XXX | XXX | XXX |
| EV (current) | $5.4B | XXX | $5.4B | XXX | XXX | XXX |
| EV/Revenue | 12.6x | XXX | 16.5x | XXX | XXX | XXX |
| EV/EBITDA | 54.7x | XXX | 109.1x | XXX | XXX | XXX |
| EV/EBIT | 58.5x | XXX | 129.9x | XXX | XXX | XXX |
| EV/Gross Profit | 14.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 75.7x | XXX | 238.2x | XXX | XXX | XXX |
| EV/FCF | 83.6x | XXX | -134.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTG Therapeutics's last 12 month revenue growth is 56%
TG Therapeutics's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.7M for the same period.
TG Therapeutics's rule of 40 is 67% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TG Therapeutics's rule of X is 162% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for TG Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 56% | XXX | 57% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 134% | XXX | 163% | XXX | XXX | XXX |
| Rule of 40 | 67% | XXX | 71% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 162% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TG Therapeutics acquired XXX companies to date.
Last acquisition by TG Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . TG Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was TG Therapeutics founded? | TG Therapeutics was founded in 1993. |
| Where is TG Therapeutics headquartered? | TG Therapeutics is headquartered in United States of America. |
| How many employees does TG Therapeutics have? | As of today, TG Therapeutics has 338 employees. |
| Who is the CEO of TG Therapeutics? | TG Therapeutics's CEO is Mr. Michael S. Weiss. |
| Is TG Therapeutics publicy listed? | Yes, TG Therapeutics is a public company listed on NAS. |
| What is the stock symbol of TG Therapeutics? | TG Therapeutics trades under TGTX ticker. |
| When did TG Therapeutics go public? | TG Therapeutics went public in 1995. |
| Who are competitors of TG Therapeutics? | Similar companies to TG Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of TG Therapeutics? | TG Therapeutics's current market cap is $5.6B |
| What is the current revenue of TG Therapeutics? | TG Therapeutics's last 12 months revenue is $433M. |
| What is the current revenue growth of TG Therapeutics? | TG Therapeutics revenue growth (NTM/LTM) is 56%. |
| What is the current EV/Revenue multiple of TG Therapeutics? | Current revenue multiple of TG Therapeutics is 12.6x. |
| Is TG Therapeutics profitable? | Yes, TG Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TG Therapeutics? | TG Therapeutics's last 12 months EBITDA is $99.6M. |
| What is TG Therapeutics's EBITDA margin? | TG Therapeutics's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of TG Therapeutics? | Current EBITDA multiple of TG Therapeutics is 54.7x. |
| What is the current FCF of TG Therapeutics? | TG Therapeutics's last 12 months FCF is $65.2M. |
| What is TG Therapeutics's FCF margin? | TG Therapeutics's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of TG Therapeutics? | Current FCF multiple of TG Therapeutics is 83.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
